NCT04047186View on ClinicalTrials.gov

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

May 30, 2025

Conditions

Multiple Pulmonary Nodules

Interventions

DRUG

Tislelizumab Injection

Patients in the experimental group receive Tislelizumab Injection

Trial Locations (1)

430030

Tongji Hospital Affiliated to Huazhong Technology Hospital, Wuhan

All Listed Sponsors

lead

XiangNing Fu

OTHER

NCT04047186 - Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules | Biotech Hunter | Biotech Hunter